SRTS logo

Sensus Healthcare, Inc. Stock Price

NasdaqCM:SRTS Community·US$62.3m Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 110 Fair Values set on narratives written by author

SRTS Share Price Performance

US$3.76
-3.41 (-47.56%)
US$13.42
Fair Value
US$3.76
-3.41 (-47.56%)
72.0% undervalued intrinsic discount
US$13.42
Fair Value
Price US$3.76
NateF US$13.42
AnalystHighTarget US$8.00
AnalystLowTarget US$6.00

SRTS Community Narratives

NateF·
Fair Value US$13.42 72.0% undervalued intrinsic discount

SRTS Market Outlook

6users have liked this narrative
0users have commented on this narrative
43users have followed this narrative
AnalystHighTarget·
Fair Value US$8 53.0% undervalued intrinsic discount

Growing Global Aging Will Expand Noninvasive Treatment Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value US$6 37.3% undervalued intrinsic discount

US Regulations Will Curtail Sales Yet Unveil Opportunities

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
SRTS logo
Sensus Healthcare

SRTS Market Outlook

Sensus Healthcare, Inc. (NASDAQ: SRTS) specializes in non-invasive treatments for skin conditions, notably through its Superficial Radiation Therapy (SRT) technology.Read more

View narrative
1.6k
users have viewed this narrative
6users have liked this narrative
0users have commented on this narrative
43users have followed this narrative
US$13.42
72.0% undervalued intrinsic discount
NateF's Fair Value
Revenue
20.39% p.a.
Profit Margin
22.54%
Future PE
12.76x
Price in 2030
US$18.35
US$6
37.3% undervalued intrinsic discount
Revenue
20.94% p.a.
Profit Margin
17.06%
Future PE
10.49x
Price in 2028
US$7.17
US$8
53.0% undervalued intrinsic discount
Revenue
19.41% p.a.
Profit Margin
14.97%
Future PE
16.57x
Price in 2028
US$9.56

Trending Discussion

Updated Narratives

SRTS logo

SRTS Market Outlook

Fair Value: US$13.42 72.0% undervalued intrinsic discount
43 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
SRTS logo

SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook

Fair Value: US$8 53.0% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
SRTS logo

Increased CMS Reimbursement And International Expansion Will Unlock Demand

Fair Value: US$8 53.0% undervalued intrinsic discount
38 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
2 Rewards

Sensus Healthcare, Inc. Key Details

US$35.6m

Revenue

US$18.5m

Cost of Revenue

US$17.1m

Gross Profit

US$20.1m

Other Expenses

-US$3.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.18
47.95%
-8.44%
0%
View Full Analysis

About SRTS

Founded
2010
Employees
54
CEO
Joseph Sardano
WebsiteView website
sensushealthcare.com

Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.

Recent SRTS News & Updates

Recent updates

No updates